Sulfonamide Porphyrins as Potent Photosensitizers against Multidrug-Resistant Staphylococcus aureus (MRSA): The Role of Co-Adjuvants

Sulfonamides are a conventional class of antibiotics that are well-suited to combat infections. However, their overuse leads to antimicrobial resistance. Porphyrins and analogs have demonstrated excellent photosensitizing properties and have been used as antimicrobial agents to photoinactivate microorganisms, including multiresistant Staphylococcus aureus (MRSA) strains. It is well recognized that the combination of different therapeutic agents might improve the biological outcome. In this present work, a novel meso-arylporphyrin and its Zn(II) complex functionalized with sulfonamide groups were synthesized and characterized and the antibacterial activity towards MRSA with and without the presence of the adjuvant KI was evaluated. For comparison, the studies were also extended to the corresponding sulfonated porphyrin TPP(SO3H)(4). Photodynamic studies revealed that all porphyrin derivatives were effective in photoinactivating MRSA (>99.9% of reduction) at a concentration of 5.0 mu M upon white light radiation with an irradiance of 25 mW cm(-2) and a total light dose of 15 J cm(-2). The combination of the porphyrin photosensitizers with the co-adjuvant KI during the photodynamic treatment proved to be very promising allowing a significant reduction in the treatment time and photosensitizer concentration by six times and at least five times, respectively. The combined effect observed for TPP(SO2NHEt)(4) and ZnTPP(SO2NHEt)(4) with KI seems to be due to the formation of reactive iodine radicals. In the photodynamic studies with TPP(SO3H)(4) plus KI, the cooperative action was mainly due to the formation of free iodine (I-2).

Automated summary

Sulfonamides are effective antibiotics against infections but misuse leads to antibiotic resistance. Porphyrins and analogs have shown good photosensitizing properties as antimicrobial agents, including against MRSA. This study synthesized and evaluated a new sulfonamide-functionalized meso-arylporphyrin and its Zn(II) complex for antibacterial activity against MRSA, both with and without the co-adjuvant KI. Photodynamic studies demonstrated effective photoinactivation of MRSA by all the porphyrin derivatives, with significantly improved outcomes when combined with KI.